from EV Nickel Inc. (isin : DE000A3CMGM5)
EQS-Adhoc: APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications
EQS-Ad-hoc: APONTIS PHARMA AG / Key word(s): Forecast/Change in Forecast
APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications
05-Apr-2024 / 10:10 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014
APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications
Monheim / Rhein, 5 April 2024. APONTIS PHARMA AG (“APONTIS PHARMA” or the “Company”, Ticker APPH / ISIN DE000A3CMGM5) has entered into a five-year agreement with Novartis Pharma GmbH to take over the distribution and marketing of two medications in the asthma indication for Germany. The Company expects a sales contribution of around EUR 9 million and an earnings contribution of up to EUR 1.5 million for the 2024 financial year. APONTIS PHARMA is therefore raising its forecast for 2024 and now expects an increase in sales to EUR 50.7 million (previously: EUR 41.7 million) and a positive EBITDA of EUR 3.3 million (previously: positive EBITDA of EUR 1.8 million).
APONTIS PHARMA AG
Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim / Rhein
Germany
apontis-pharma.de
APONTIS PHARMA press contact
CROSS ALLIANCE communication GmbH
Sven Pauly
ir@apontis-pharma.de
T: +49 89 125 09 0330
End of Inside Information
05-Apr-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | APONTIS PHARMA AG |
| Alfred-Nobel-Str. 10 | |
| 40789 Monheim | |
| Germany | |
| E-mail: | ir@apontis-pharma.de |
| Internet: | https://apontis-pharma.de/ |
| ISIN: | DE000A3CMGM5 |
| WKN: | A3CMGM |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1873383 |
| End of Announcement | EQS News Service |
1873383 05-Apr-2024 CET/CEST